MERHAUTOVÁ, Jana, Renata HÉŽOVÁ, Alexandr POPRACH, Alena KOVAŘÍKOVÁ, Lenka RADOVÁ, Marek SVOBODA, Rostislav VYZULA, Regina DEMLOVÁ and Ondřej SLABÝ. miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. BioMed Research International. New York: Hindawi Publishing Corporation, 2015, vol. 2015, No 941980, p. 1-5. ISSN 2314-6133. doi:10.1155/2015/941980.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib
Authors MERHAUTOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Renata HÉŽOVÁ (203 Czech Republic, belonging to the institution), Alexandr POPRACH (203 Czech Republic, belonging to the institution), Alena KOVAŘÍKOVÁ (203 Czech Republic, belonging to the institution), Lenka RADOVÁ (203 Czech Republic, belonging to the institution), Marek SVOBODA (203 Czech Republic, belonging to the institution), Rostislav VYZULA (203 Czech Republic, belonging to the institution), Regina DEMLOVÁ (203 Czech Republic, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, belonging to the institution).
Edition BioMed Research International, New York, Hindawi Publishing Corporation, 2015, 2314-6133.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.134
RIV identification code RIV/00216224:14110/15:00082807
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1155/2015/941980
UT WoS 000354699400001
Keywords in English microRNA; renal cell carcinoma; sunitinib
Tags EL OK, podil
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 3. 8. 2015 14:38.
Abstract
Background. Sunitinib is a tyrosine kinase inhibitor used in the treatment of metastatic renal cell carcinoma. The main difficulty related to the treatment is the development of drug resistance followed by rapid progression of the disease. We analyzed tumor tissue of sunitinib treated patients in order to find miRNAs associated with therapeutic response. Methods. A total of 79 patients with metastatic renal cell carcinoma were included in our study. miRNA profiling in tumor tissue samples was performed by TaqMan Low Density Arrays and a group of selected miRNAs (miR-155, miR-374-5p, miR-324-3p, miR-484, miR-302c, and miR-888) was further validated by qRT-PCR. Normalized data were subjected to ROC and Kaplan-Meier analysis. Results. We reported decreased tissue levels of miR-155 and miR-484 as significantly associated with increased time to progression (miR-155: median TTP 5.8 versus 12.8 months, miR-484: median TTP 5.8 versus 8.9 months). Conclusion. miR-155 and miR-484 are potentially connected with sunitinib resistance and failure of the therapy. miR-155 is a known oncogene with direct influence on neovascularization. Biological role of miR-484 has to be clarified. Stratification of patients based on miRNA analysis would allow more personalized approach in therapy of metastatic renal cell carcinoma.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
NT13547, research and development projectName: Studium mikroRNA a genů asociovaných s procesem epiteliálně-mezenchymální tranzice jako potenciálních markerů pro predikci rizika a časný záchyt metastazování u pacientů s renálním karcinomem
NV15-34678A, research and development projectName: Molekulární prognostické a prediktivní faktory u pacientů s metastatickým renálním karcinomem léčených tyrozinkinázovými inhibitory
PrintDisplayed: 29. 9. 2022 12:36